Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma.
Zugasti I, Tormo-Ratera M, Oliver-Caldes A, Soler-Perromat JC, Gonzalez-Calle V, Moreno DF, Cabañas V, Lopez-Muñoz N, Bartolome-Solanas A, Español-Rego M, Reguera-Ortega JL, Rosiñol L, Lopez-Corral L, Tovar N, Rodríguez-Lobato LG, Alvarez Perez RM, Varea S, Olesti E, Gomez Grande A, Frutos L, Tamayo P, Juan M, Moraleda JM, Urbano-Ispizua Á, González-Navarro EAA, Martínez-López J, Mateos MV, Tomas X, Setoain X, Fernández de Larrea C. Zugasti I, et al. Blood Adv. 2024 Nov 27:bloodadvances.2024014360. doi: 10.1182/bloodadvances.2024014360. Online ahead of print. Blood Adv. 2024. PMID: 39602341
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.
Castaño-Díez S, López-Guerra M, Zugasti I, Calvo X, Schulz FI, Avendaño A, Mora E, Falantes J, Azaceta G, Ibáñez M, Chen T, Notario C, Amer N, Palomo L, Pomares H, Vila J, Bernal Del Castillo T, Jiménez-Vicente C, Esteban D, Guijarro F, Álamo J, Cortés-Bullich A, Torrecillas-Mayayo V, Triguero A, Mont-de Torres L, Carcelero E, Cardús A, Germing U, Betz B, Rozman M, Arenillas L, Zamora L, Díez-Campelo M, Xicoy B, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: zugasti i. Blood Adv. 2025 Jan 14;9(1):39-53. doi: 10.1182/bloodadvances.2024013648. Blood Adv. 2025. PMID: 39388660
Chronic myelomonocytic leukemia with NPM1 mutation or acute myeloid leukemia?
Castaño-Díez S, Álamo JR, López-Guerra M, Gómez-Hernando M, Zugasti I, Jiménez-Vicente C, Guijarro F, López-Oreja I, Esteban D, Charry P, Torrecillas V, Mont-de Torres L, Cortés-Bullich A, Bataller Á, Guardia A, Munárriz D, Carcelero E, Riu G, Triguero A, Tovar N, Vela D, Beà S, Costa D, Colomer D, Rozman M, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: zugasti i. Oncologist. 2024 Sep 30:oyae246. doi: 10.1093/oncolo/oyae246. Online ahead of print. Oncologist. 2024. PMID: 39349391 Free article.
Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study.
Jiménez-Vicente C, Guardia-Torrelles A, Pérez-Valencia AI, Martínez-Roca A, Castaño-Diez S, Guijarro F, Cortés-Bullich A, Merchán B, Triguero A, Hernández I, Brillembourg H, Munárriz D, Zugasti I, Fernández-Avilés F, Diaz-Beyá M, Esteve J. Jiménez-Vicente C, et al. Among authors: zugasti i. Ann Hematol. 2024 Oct;103(10):4033-4043. doi: 10.1007/s00277-024-05923-5. Epub 2024 Aug 29. Ann Hematol. 2024. PMID: 39207559 Free PMC article.
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells.
Ortiz de Landazuri I, Oliver-Caldés A, Español-Rego M, Agulló C, Contreras MT, Zabaleta A, Puig N, Cabañas V, González-Calle V, Zugasti I, Inogés S, Rodríguez Otero P, Martin-Antonio B, Reguera JL, López-Diaz de Cerio A, Aróstegui JI, Uribe-Herranz M, Benítez-Ribas D, Rodríguez-Lobato LG, González EA, Tovar N, Charry P, Navarro S, Rosiñol L, Tréboles K, Mora G, Yagüe J, Moraleda JM, Urbano-Ispizua Á, Mateos MV, Pascal M, Paiva B, Juan M, Fernández de Larrea C. Ortiz de Landazuri I, et al. Among authors: zugasti i. Br J Haematol. 2024 Oct;205(4):1346-1355. doi: 10.1111/bjh.19589. Epub 2024 Jun 18. Br J Haematol. 2024. PMID: 38894496
Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
Castaño-Díez S, Pomares H, Esteban D, Guijarro F, Jiménez-Vicente C, Zugasti I, Álamo JR, Mayayo VT, López-Guerra M, de la Fuente C, Charry P, Cortés-Bullich A, Bataller Á, Maluquer C, Colomer D, Rozman M, Arnan M, Xicoy B, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: zugasti i. Br J Haematol. 2024 Mar;204(3):892-897. doi: 10.1111/bjh.19217. Epub 2023 Nov 27. Br J Haematol. 2024. PMID: 38013238
Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
Jiménez-Vicente C, Martínez-Roca A, Pomares H, Castaño-Diez S, Guijarro F, López-Guerra M, Bataller A, Esteban D, Cortés-Bullich A, Pérez-Valencia AI, Guardia-Torrelles A, Zugasti I, Rovira M, Fernández-Avilés F, Colomer D, Arnan M, Díaz-Beyá M, Esteve J. Jiménez-Vicente C, et al. Among authors: zugasti i. Leuk Res. 2023 Dec;135:107403. doi: 10.1016/j.leukres.2023.107403. Epub 2023 Sep 30. Leuk Res. 2023. PMID: 37837718 No abstract available.
15 results